CMS RBCS · Treatments · Injections and Infusions (nononcologic)

Injection - Tumor Necrosis Factor Blocker codes

2 CPT®/HCPCS codes, ranked by est. all-Medicare services — scaled from national Medicare Part B fee-for-service volume. Open any code for the full market view — ranked physician groups, geography, and 12-year trend.

CY2024 · National scale is an all-Medicare estimate · est. — scaled estimate — assumes MA utilization mirrors FFS; not an observation; the observed fee-for-service figure is shown adjacent. Part B · national figures

HCPCS · Treatment J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) CMS descriptor · HCPCS
Medicare Part B claims

First observed 2014 — first year this code appears in Part B claims

National scale 123.08M services · est. ▲ 14.9% YoY · 26,374 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 61.17M observed fee-for-service services

See the national market for J0717 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1602 Injection, golimumab, 1 mg, for intravenous use CMS descriptor · HCPCS
Medicare Part B claims

First observed 2014 — first year this code appears in Part B claims

National scale 40.28M services · est. ▲ 8.5% YoY · 33,757 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 19.86M observed fee-for-service services

See the national market for J1602 → ranked groups · states · 12-yr trend